CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., today announced the appointment of Dr. Geoffrey R. Oxnard as vice president, global medical lead for the Company’s liquid biopsy portfolio, effective immediately. He joins Foundation Medicine from Dana-Farber Cancer Institute, Harvard Medical School, where he has worked as a thoracic oncologist and a Damon Runyon Clinical Investigator.
Dr. Oxnard brings 10 years of unique experience studying genomic biomarkers of drug sensitivity and resistance and developing trials to pilot new diagnostics in the clinic. His recent research has focused on the clinical application of liquid biopsy technologies to understand drug resistance for selecting targeted therapies, and for detecting occult cancer.
“Throughout his career, Geoff has been dedicated to expanding the understanding of precision medicine approaches and is widely recognized as a pioneering thought leader in the use of liquid biopsy to help doctors and patients make critical treatment decisions and improving the treatment options available to patients,” said Brian Alexander, M.D., M.P.H., chief medical officer at Foundation Medicine. “His experience positions him well to collaborate across our Medical and R&D teams to support the expansion of our liquid biopsy portfolio through research, publications and the assessment of new technologies.”
In his new role, Dr. Oxnard will work cross-functionally to help define research, as well as a liquid biopsy-focused discovery roadmap. With his experience as both a clinician and a translational researcher, he will partner with the team to develop the reach and understanding of liquid biopsy comprehensive genomic profiling testing for physicians, payers and policymakers. He will also collaborate broadly across the cancer community to investigate novel applications of liquid biopsy approaches to improve cancer care and research.
“Over the past decade, I have been excited by the work Foundation Medicine has done to help transform the way physicians think about treating cancer,” Dr. Oxnard said. “Foundation Medicine has made impressive strides in precision medicine research, such as its involvement in the first-of-its-kind BFAST trial, to advance the field of liquid biopsy testing. I look forward to working with this team of innovative thinkers to develop more robust strategies for how we can expand Foundation Medicine’s insights and offerings to the cancer community, and most importantly, to patients.”
Dr. Oxnard will continue to see patients on a part-time basis at the Dana-Farber Cancer Institute in the Lowe Center for Thoracic Oncology. He is a graduate of the University of Chicago Pritzker School of Medicine, completed his residency in internal medicine at Massachusetts General Hospital, and his fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
Source: Foundation Medicine
